Lung Cancer’s Dominance: The Largest Single Application Segment in the India Keytruda Market

In terms of clinical application and revenue contribution, Non-Small Cell Lung Cancer (NSCLC) remains the single largest and most influential segment in the India Keytruda Market, driving the highest procedural volume.

Lung cancer is one of the most common and deadliest cancers globally, and its incidence continues to rise in India. Keytruda has demonstrated profound efficacy, particularly in first-line treatment for PD-L1 positive NSCLC, both as monotherapy and in combination with chemotherapy, establishing it as the standard of care.

The early use of Keytruda in the metastatic and advanced stages of this high-volume, high-mortality cancer type ensures a continuous flow of prescriptions. This established clinical protocol and the high patient turnover rate secure Lung Cancer’s role as the anchor segment of the India Keytruda Market.

FAQ

Q: Why is NSCLC such a critical revenue driver for Keytruda? A: It is a high-incidence cancer where Keytruda is used early in the treatment line (first-line monotherapy or combination therapy) for PD-L1 positive cases, making it the standard of care.

Q: What biomarker test is crucial for determining if a lung cancer patient should receive Keytruda monotherapy? A: The PD-L1 expression level, often measured as the Combined Positive Score (CPS), guides the decision for initial monotherapy treatment

Upgrade auf Pro
Wähle den für dich passenden Plan aus
Bub

Do?

Mehr lesen
Gigg https://sierra-le.com